 Galapagos NV NASDAQ: GLPG and Gilead Sciences Inc NASDAQ: GILD have decided to stop the ISABELA Phase 3 studies evaluating ziritaxestat in patients with idiopathic pulmonary fibrosis IPF. All clinical trials with ziritaxestat, including the long-term extension of the Phase 2a NOVESA trial in systemic sclerosis, will be discontinued as well. 